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The aldo–keto reductases (AKRs) are a superfamily of NAD(P)H-linked oxidoreductases,
which reduce aldehydes and ketones to their respective primary and secondary alcohols.
AKR enzymes are increasingly being recognized to play an important role in the transfor-
mation and detoxiﬁcation of aldehydes and ketones generated during drug detoxiﬁcation
and xenobiotic metabolism. Many transcription factors have been identiﬁed to regulate the
expression of human AKR genes, which could have profound effects on the metabolism of
endogenous mediators and detoxication of chemical carcinogens.This review summarizes
the current knowledge on AKR regulation by transcription factors and other mediators in
human diseases.
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INTRODUCTION
The aldo–keto reductases (AKRs) are a superfamily of NAD(P)H-
linked oxidoreductases, which primarily catalyze the reduction of
aldehydes and ketones to primary and secondary alcohols, respec-
tively (Penning and Drury, 2007). AKRs are generally soluble,
cytosolic monomeric (37 kDa) enzymes and are present in both
prokaryotes and eukaryotes. These enzymes share a common pro-
tein fold, a (β/α)8 or a triosephosphate isomerase (TIM)-barrel,
and have an active site in the C-terminal face (Jez et al., 1997a,b;
Barski et al., 2008). Most AKRs use pyridine nucleotide as cofac-
tors and catalyze simple oxidation–reduction reactions involved
in the metabolism of sugar aldehydes, reactive lipid aldehydes,
ketoprostaglandins, and ketosteroids.
Aldo–keto reductases consist of 15 families which have
more than 100 members (Barski et al., 2008). There are 13
human AKR proteins that fall into 3 families AKR1, AKR6,
and AKR7 (Table 1). The detailed information is available at
http://www.med.upenn.edu/akr, an AKR superfamily homepage,
maintained by Dr. T. Penning at the University of Pennsylvania.
The human AKR enzymes include AKR1A1 (aldehyde reductase),
AKR1B1 andAKR1B10 (aldose reductases),AKR1C1–C4 (hydrox-
ysteroid dehydrogenases), AKR1D1 (steroid 5β-reductase), the
AKR6 family (AKR6A3, A5, and A9; Kvβ proteins), and the
AKR7 family (AKR7A2 and AKR7A3; aﬂatoxin aldehyde reduc-
tases). These human AKR enzymes can catalyze many meta-
bolic oxidation–reduction reactions of numerous endogenous
and exogenous substrates, including glucose, steroids, carcino-
gens, reactive aldehydes, and a variety of carbonyl-containing
drugs. To date, the AKR enzymes have been implicated in a num-
ber of human diseases. It is known that AKR1A1, AKR1B10,
and AKR1C1–C3 are involved in tobacco-induced carcinogen-
esis (Hsu et al., 2001; Penning, 2005; Jin and Penning, 2007;
Zhang et al., 2008; Liu et al., 2009a). Inhibition of AKR1B1 is
able to alleviate diabetic complications. Throughmediating oxida-
tive stress-induced inﬂammatory signals, AKR1B1 plays a role in
inﬂammation-related diseases such as sepsis and colon cancer
(Ramana, 2011). AKR1B1 and AKR1B10 regulate the develop-
ment and progression of human liver, breast, and lung cancers
through detoxifying reactive carbonyls, retinoic acid homeostatic
regulation, and lipid metabolism (Liu et al., 2009a; Diez-Dacal
et al., 2011). AKR1C1–C3 enzymes are involved in prostate and
breast carcinogenesis (Penning and Byrns, 2009). Mutations in
AKR1D1 gene in patients lead to neonatal cholestasis, hepatitis,
and liver failure (Lemonde et al., 2003; Barski et al., 2008). AKR7A
proteins protect liver from acetaminophen-induced hepatotoxic-
ity by enhancing hepatocellular antioxidant defense (Ahmed et al.,
2011). Because AKR enzymes are increasingly being recognized
to play a role in various diseases, understanding the regulation
of human AKR genes may help us develop novel therapeutic
approaches. In this review, we summarize the regulation of AKRs
by transcription factors, mediators, and pathological conditions.
THE REGULATION OF AKRs
Many transcription factors have been identiﬁed to regulate the
expression of human AKR genes, which could have profound
effects on the metabolism of endogenous mediators and detox-
ication of chemical carcinogens. Several classes of transcription
enhancer elements have been identiﬁed in the upstream pro-
moter region of AKR genes that include nuclear receptor response
elements, AP-1 binding sites, the xenobiotic response elements
(XRE), osmotic response elements (ORE), estrogen response ele-
ments (ERE), and antioxidant response elements (ARE; Ko et al.,
1997; Burczynski et al., 1999; Lou et al., 2006; Penning and Drury,
2007).
AKR1A1
AKR1A1, a ubiquitously expressed enzyme, is a well-known
cytosolic, NADPH-dependent and monomeric oxidoreductase.
AKR1A1 participates in carbonyl reductions of chemotherapeutic
drugs. Protein andmRNA levels of AKR1A1 in irinotecan-resistant
LoVo cells are higher than in human colon adenocarcinoma LoVo
cells (Peng et al., 2010). Recent studies suggest that overexpression
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Table 1 | Regulation of human aldo–keto reductase.
Name Enzyme Previous symbols Synonyms Regulation
AKR1A1 Aldehyde reductase ALR, DD3 hStaf/ZNF143, C/EBP, PPARγ, atorvastatin
AKR1B1 Aldose reductase ALDR1 AR Thyroid hormone, CREB, NAFT5, Nrf2,
nitric oxide, EGF, TGFβ1, atorvastatin
AKR1B10 Aldose reductase AKR1B11 AKR1B12, ARL-1, HIS, ARL1,
HSI, ALDRLn
Mouse Akr1b7 is regulated by LXR, PXR,
CAR, FXR
AKR1C1 Dihydrodiol dehydrogenase 1; 20-alpha
(3-alpha)-hydroxysteroid
dehydrogenase
DDH1 DDH, MBAB, DD1, HAKRC Sp1, NF-Y, IL-1β
AKR1C2 Dihydrodiol dehydrogenase 2; bile acid
binding protein; 3-alpha hydroxysteroid
dehydrogenase, type III
DDH2 DD, BABP, DD2, HAKRD,
MCDR2
IL-1β
AKR1C3 Aldo–keto reductase family 1, member
C3 (3-alpha hydroxysteroid
dehydrogenase, type II)
HSD17B5 KIAA0119, DDX, HAKRB IL-6, cadmium, Nrf2
AKR1C4 Chlordecone reductase; 3-alpha
hydroxysteroid dehydrogenase, type I;
dihydrodiol dehydrogenase 4




AKR1D1 Delta 4-3-ketosteroid-5-beta-reductase SRD5B1 Estrogen
AKR6A3 Shaker channel β-subunit (Kvb1) KCNAB1, KCNA1B,
hKvBeta3, Kvb1.3, hKvb3
Bone morphogenic protein-2
AKR6A5 Shaker channel β-subunit (Kvb2) KCNAB2, KCNA2B,
HKvbeta2.1, HKvbeta2.2
AKR6A9 Shaker channel β-subunit (Kvb1) KCNAB3, KCNA3B
AKR7A2 Aﬂatoxin aldehyde reductase AFAR Nrf2, acetaminophen
AKR7A3 Aﬂatoxin aldehyde reductase Nrf2, acetaminophen
References and the regulation of AKRs by pathological conditions can be found in the text.
of AKR1A1 may protect lung epithelial cells against acute toxic
effects of polycyclic aromatic hydrocarbon metabolites (Abedin
et al., 2012).
Gel-shift assays and chromatin immunoprecipitation assays
revealed that AKR1A1 is a target gene of transcription fac-
tors hStaf/ZNF143 and C/EBP homologous protein (Table 1;
Barski et al., 2004; Myslinski et al., 2006). The β-hydroxy-
β-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor
atorvastatin suppresses the expression of AKR1A1 and AKR1B1
in human umbilical vein endothelial cells (HUVEC) but not
in human proximal tubular epithelial cells (Ruf et al., 2009).
Luciferase reporter assays showed that atorvastatin regulates
AKR1A1 promoter activity through an ARE (Ruf et al., 2009).
Grip et al. (2002) show that atorvastatin also activates PPARγ.
The PPARγ binding sites are also found in the AKR1A1 promoter.
Thus, atorvastatin may regulate AKR1A1 expression via direct or
indirect regulation of AKR1A1 promoter activity.
AKR1B1 AND AKR1B10
AKR1B1, themost studiedAKR familymember, is the rate-limiting
enzyme of the polyol pathway. AKR1B1 has long been known
for its potential role in the development of diabetic complica-
tions by driving glucose ﬂux through the polyol pathway (Liu
et al., 2009a). Because this enzyme catalyzes the reduction of
glucose to a sugar alcohol, many AKR1B1 inhibitors have been
developed for the treatment of diabetic complications. Recent
reports showed that AKR1B1 is also involved in inﬂammatory
diseases such as atherosclerosis, sepsis, uveitis, and colon car-
cinogenesis through regulating oxidative stress-induced inﬂam-
matory signals (Ramana, 2011; Shoeb et al., 2011). The AKR1B1
and AKR1B10 have 71% identify in amino acid sequence. These
two proteins show overlapped substrate speciﬁcity but signiﬁ-
cantly different tissue expression patterns.AKR1B1 is ubiquitously
expressed whereas AKR1B10 is mainly expressed in liver, colon,
small intestine, thymus, and adrenal gland. AKR1B10 was identi-
ﬁed in 1998. Recent results suggest that AKR1B10 may be a tumor
marker of several types of cancers. For example,Wang et al. (2010)
reported that smoking can induce up-regulation of AKR1B10 in
the airway epithelium, suggesting that increasedAKR1B10 expres-
sion may be involved in lung carcinogenesis. Increased expression
of AKR1B1 and AKR1B10 has been found in human liver, breast,
and lung tumors. Thus these two proteins may play a key role in
the development and progression of these types of cancers (Liu
et al., 2009a; Kropotova et al., 2010).
The AKR1B1 gene is up-regulated in response to thyroid
hormone (T3) treatment. Liao et al. (2009) reported that T3-
bound thyroid hormone receptor (TR) induced AKR1B1 expres-
sion through a T3 response element; they also demonstrated that
AKR1B1 overexpression in some types of hepatocellular carcino-
mas (HCCs) was TR-dependent, suggesting that the TR-AKR1B1
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pathway might play a crucial role in the development of HCC.
Lefrancois-Martinez et al. (2004) indicated that AKR1B1 expres-
sion in human adrenocortical cells may be regulated by the
transcription factor cAMP-responsive element-binding protein
(CREB). Yang et al. (2006) showed that the expression of AKR1B1
is tightly regulated by the transcription factor nuclear factor of
activated T-cells 5 (NFAT5) through binding to OREs in the gene.
Recently, the transcription factor nuclear factor-erythroid 2 related
factor 2 (Nrf2), a key regulator in the adaptive response to oxidative
stress,was shown to regulate the expression of AKR1B1,AKR1B10,
and AKR1C1–C3 (Ebert et al., 2011; Nishinaka et al., 2011).
Finally, several groups observed that theAKR1B1 expression is up-
regulated in response to the treatment of nitric oxide (Seo et al.,
2000), hydrogen peroxide, methylglyoxal (Yabe-Nishimura et al.,
2003), epidermal growth factor, or transforming growth factor-β1
(Jiang et al., 2008).
The closest murine ortholog of human AKR1B10 is Akr1b7,
which is also expressed in the liver, intestine, and adrenal gland.
Murine Akr1b7 shares 89% amino acid homology with human
AKR1B10. There are several nuclear receptor binding sites in
the Akr1b7 promoter (Figure 1). Several groups have identiﬁed
Akr1b7 as a direct target of nuclear receptors, such as liver X
receptor (LXR; Volle et al., 2004), xenobiotic receptors pregnane
X receptor (PXR), constitutive androstane receptor (CAR), and
farnesoid X receptor (FXR; Figure 1). The ﬁnding that Akr1b7 is
highly inducible by PXR and CAR (Liu et al., 2009b), is consistent
with the role of Akr1b7 in xenobiotic metabolism and lipid per-
oxidation. Schmidt et al. (2011) showed that FXR induces Akr1b7
expression in the liver and intestine and that Akr1b7 plays a role in
detoxiﬁcation of speciﬁc bile acids. We found that hepatic and
intestinal Akr1b7 is highly inducible by FXR and that Akr1b7
has striking effects on lowering blood glucose levels and reduc-
ing hepatic lipid accumulation in diabetic mice (Ge et al., 2011).
These effects are associated with reduced expression of hepatic
gluconeogenic genes and increased very low-density lipoprotein
secretion. Our data suggest that AKR1b7 may be a therapeutic
target for treatment of diabetes mellitus. It will be intriguing to
investigate whether human AKR1B10 also regulates glucose and
lipid metabolism.
AKR1C1–C4
AKR1C1–C4 share over 86% homology with each other. AKR1C1
is expressed in liver, kidney, and testis.AKR1C2 ismainly expressed
in liver, prostate, and mammary gland. AKR1C3 is expressed in
liver, brain, kidney, placenta, and testis. AKR1C4 is speciﬁcally
expressed in liver. These enzymes are involved in the metabo-
lism of steroid hormones (AKR1C1–AKR1C3), prostaglandins
(AKR1C3), and bile acids (AKR1C4), and play important roles
in the detoxiﬁcation of drugs and xenobiotics (Ebert et al.,
2011). AKR1C1–C3 enzymes may be involved in tobacco-induced
prostate and breast carcinogenesis (Penning and Byrns, 2009).
Increased expression of AKR1C1 has been detected in human
diseases, such as endometriosis (Smuc et al., 2009; Hevir et al.,
2011), androgen-independent prostate cancer (Stanbrough et al.,
2006), and lung cancer (Hsu et al., 2001). Increased expression of
AKR1C3 is found in leukemia (Mahadevan et al., 2006; Birtwistle
et al., 2009), prostate cancer (Fung et al., 2006; Stanbrough et al.,
2006), and breast cancer (Penning and Byrns, 2009).
AKR1C1 overexpression has been associated with drug-
resistance in a variety of cancers (Deng et al., 2002, 2004; Chen
et al., 2005; Hung et al., 2006). Some anticancer drugs may
be metabolized by AKR1C1 due to the high similarity between
the chemical structures of these drugs and AKR1C1 substrates
(Selga et al., 2008). It has been proposed that increased AKR1C1
activity would detoxify reactive oxygen species induced by drugs
such as cisplatin, and could lead to apoptosis-related develop-
ment of drug-resistance. Selga et al. (2008) suggest that AKR1C1
gene expression is regulated by Sp1 transcription factor, and
suppression of AKR1C1 by RNA interference (RNAi) improves
the sensitivity to methotrexate, an antimetabolite drug for the
chemotherapy of human malignancies, in methotrexate sensitive
HT29 cells. The transcription factor, nuclear factor-Y (NF-Y) has
also been reported to directly regulate the basal transcription of
AKR1C1 in human ovarian, lung, and liver carcinoma cells (Pal-
lai et al., 2010). Interleukin 1β (IL-1β), a major proinﬂammatory
cytokine, can signiﬁcantly induce the expression of both AKR1C1
and AKR1C2. Roberson et al. (2011) recently showed that this
cytokine can facilitate local progesterone metabolism in a cell
type critical for maintaining cervical structure through regulating
FIGURE 1 | Regulation of the Akr1b7 promoter activity by nuclear
receptors.The DNA binding sites, including the FXR response
element (FXRE), LXR response element (LXRE), PXR response
element (PXRE), and CAR response element (CARE) are shown.
There are three LXR binding sites (LXRE1-3) in the Akr1b7 promoter.
In response to speciﬁc ligand treatments, the PXR/RXR, CAR/RXR,
and LXR/RXR heterodimers bind to the same binding site (LXRE2) in
the Akr1b7 promoter.
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expression of AKR1C1 and AKR1C2. Chun et al. (2009) reported
that IL-6 induces the expression of AKR1C3. Cadmium is a toxic
metal. Occupational exposure to cadmium is related to the devel-
opment of lung cancer. Lee et al. (2011) reported that cadmium
induces AKR1C3 gene expression through activation of PI3K-
related intracellular signaling pathways and Nrf2 activation. The
signiﬁcance in induction of AKR1C3 by IL-6 or cadmium remains
to be explored.
It is well documented that liver X receptor (LXR), a nuclear
receptor for oxysterols, plays an important role in the regulation
of bile acid, lipid, and carbohydrate metabolism and inﬂamma-
tion. AKR1C4 has been demonstrated to be a direct target gene
of LXR (Stayrook et al., 2008). Thus, AKR1C4 may play a role in
LXR-regulated metabolism or inﬂammation.
OTHERS
AKR1D1 catalyzes the 5-β-reduction of bile acid intermediates
and steroid hormones which carry a delta (4)-3-one structure.
AKR1D1 is expressed in liver, colon, brain, and testis (Charbon-
neau andThe,2001; Jin et al., 2011).Deﬁciency of this enzymemay
contribute to hepatic dysfunction (Lemonde et al., 2003; Gonzales
et al., 2004; Clayton, 2011). Mutations in human AKR1D1 gene
lead to neonatal cholestasis, hepatitis, and liver failure (Barski
et al., 2008). In addition, AKR1D1 may play an important role
in the degradative metabolism of sex hormones and in regu-
lating multiple hormone-dependent processes. Mode and Rafter
(1985) observed different levels of AKR1D1 in the liver of males
and females. The ERE was found in the promoter of this gene,
suggesting that AKR1D1 may be regulated by estrogen.
AKR6A3, A5, A9 are potassium voltage-gated channel beta-
subunits, which are expressed in heart and brain. Fantozzi et al.
(2006) suggested that bone morphogenetic protein-2 may sup-
press the expression of AKR6A3. AKR6A3 andAKR6A5 have been
associated with epilepsy and impairment of learning and memory
(Busolin et al., 2011;Wakasaya et al., 2011). Deletion of AKR6A5 is
often detected in patients who havemonosomy 1p36 deletion syn-
drome, which is characterized by learning disabilities (Perkowski
and Murphy, 2011). By far, little is known about the regulation of
AKR6A5 or A9.
AKR7A2 and AKR7A3 are aﬂatoxin dialdehyde reductases,
which share the same chromosomal localization. These enzymes
play important roles in bioactivation and biodetoxiﬁcation (Barski
et al., 2008). AKR7A2 is a ubiquitously expressed enzyme, whereas
the expression of AKR7A3 is limited to the liver, kidney, colon,
pancreas, stomach, endometrium, and adenocarcinoma. Previ-
ous studies suggested that AKR7A2 and A3, like other sub-
groups in the AKR superfamily, are transcriptionally regulated
by oxidative stress-responsive transcription factor Nrf2. Ahmed
et al. (2011) showed that AKR7A proteins are signiﬁcantly up-
regulated in response to acetaminophen exposure and protect liver
from acetaminophen-induced hepatotoxicity through enhancing
hepatocellular antioxidant defense.
CONCLUSION
Aldo–keto reductase enzymes play an important role in the trans-
formation and detoxiﬁcation of aldehydes and ketones. They are
involved in bile acid, lipid, carbohydrate, and xenobiotic metabo-
lism, and in inﬂammation and carcinogenesis. By far, our under-
standing of the regulation of human AKRs remains limited. Fur-
ther investigation of the regulation of human AKRs and AKR’s
functions under normal and pathological conditional will help
develop novel therapeutic approaches for treatment of metabolic
disorders, inﬂammation, cancer, and other relevant diseases.
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